论文部分内容阅读
目的:观察多西他赛联合吡柔比星化疗(新辅助化疗)对雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(HER-2)的影响。方法:选择确诊乳腺癌76例,采用新辅助化疗方案,21天为1个周期,疗程结束后15～20天手术;术中切标本行常规病理检查及免疫组织化学检查,观察新辅助化疗前后ER、PR、HER-2表达水平的变化。结果:76例中,术后病理学完全缓解3例;未达到病理完全缓解的73例中,化疗后ER表达水平较化疗前变化不显著(P>0.05);PR、HER-2表达水平较化疗前显著下调(P<0.05)。结论:新辅助化疗后PR、HER-2水平下调,可能会对部分患者的预后产生影响。
Objective: To observe the effect of docetaxel combined with pirarubicin (neoadjuvant chemotherapy) on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). Methods: Totally 76 breast cancer patients were selected. The neoadjuvant chemotherapy regimen was used. One cycle was performed on 21 days. The operation was performed 15 to 20 days after the end of treatment. Conventional histological examinations and immunohistochemical examinations were performed to observe the effects of neoadjuvant chemotherapy ER, PR, HER-2 expression level changes. Results: Of the 76 cases, postoperative pathology was completely relieved in 3 cases. Among the 73 cases that did not achieve complete remission, the expression of ER was not significantly changed after chemotherapy (P> 0.05). The expression of PR and HER-2 Significantly decreased before chemotherapy (P <0.05). Conclusion: The down-regulation of PR and HER-2 levels after neoadjuvant chemotherapy may affect the prognosis of some patients.